★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
editor@theamericanjournals.comPublisher Home ↗
Medical Science OPEN ACCESS

Prognostic Significance Of Endothelin-1 In Patients With Unstable Angina

Sabirova Azizaxon Dilshodovna
Tashkent State Medical University Multidisciplinary Clinic, Department of Cardiology. Cardiologist, Tashkent, 100109, Uzbekistan
Abdashimov Zafar Bakhtiyarovich
Deputy Chief Medical Officer, TDTU Multidisciplinary Clinic, Clinical Pharmacologist, Tashkent, 100109, Uzbekistan
Nurillayeva Nargiza Mukhtarkhanovna
MD, PhD, Professor, Department of Internal Diseases in Family Medicine No. 1 and Fundamentals of Preventive Medicine, Tashkent State Medical University, Tashkent, 100109, Uzbekistan
DOI Crossref DOI 10.37547/tajmspr/Volume07Issue12-12
tajmspr 2025
VOL. 7 / NO. 12 DECEMBER
FULL TEXT PP. 83-86
DOWNLOAD PDF

View all articles in this issue ↗

VOLUME 7
ISSUE 12
YEAR 2025
PAGES 83-86
RESEARCH OVERVIEW

Abstract

Background: Endothelial dysfunction is a key pathophysiological mechanism underlying acute coronary syndromes. Endothelin-1 (ET-1), one of the most potent endogenous vasoconstrictors, plays a central role in coronary vasomotor dysregulation, inflammation, oxidative stress, and plaque instability. Despite growing interest in endothelin-mediated pathways, the clinical and prognostic significance of ET-1 in unstable angina remains insufficiently characterized, particularly in Central Asian populations. Objective: To investigate serum endothelin-1 levels in patients with unstable angina, to assess their association with clinical severity, ischemic burden, inflammatory activity, and to evaluate their prognostic value during short-term follow-up. Methods: A prospective observational study was conducted between 2024 and 2025 in tertiary cardiology centers in Tashkent, Uzbekistan. A total of 112 patients with unstable angina and 40 apparently healthy controls were enrolled. Serum ET-1 concentrations were measured using enzyme-linked immunosorbent assay. Clinical characteristics, frequency of angina attacks, ambulatory ECG monitoring parameters, and inflammatory markers were analyzed. Patients were followed for early adverse cardiovascular events. Results: Patients with unstable angina exhibited significantly higher ET-1 levels compared with controls (0.78 ± 0.21 vs. 0.26 ± 0.09 fmol/mL, p < 0.001). Elevated ET-1 was associated with increased ischemic burden, recurrent angina episodes, and unfavorable ECG patterns. A strong positive correlation was observed between ET-1 concentration and angina frequency (r = 0.54, p < 0.01). Persistently elevated ET-1 levels were predictive of early adverse cardiovascular outcomes. Conclusion: Endothelin-1 is a sensitive marker of endothelial dysfunction and an independent predictor of disease severity and short-term prognosis in unstable angina. Routine assessment of ET-1 may enhance risk stratification and guide personalized therapeutic strategies in acute coronary syndromes.

RESEARCH TOPICS

Keywords

Endothelin-1 unstable angina endothelial dysfunction

Downloads

Download data is not yet available.
SOURCES & SCHOLARSHIP

References

  1. World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  2. Collet JP, Thiele H, Barbato E, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191
  3. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874. doi:10.1038/nature01323
  4. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi:10.1056/NEJM199901143400207
  5. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111(3):363–368. doi:10.1161/01.CIR.0000153339.27064.14
  6. Böhm F, Pernow J. Endothelin-1 and cardiovascular disease. J Intern Med. 2007;261(1):1–20. doi:10.1111/j.1365-2796.2006.01731.x
  7. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. J Am Coll Cardiol. 2019;74(4):557–575. doi:10.1016/j.jacc.2019.05.052
  8. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Hypertension. 2001;37(2):582–587. doi:10.1161/01.HYP.37.2.582
  9. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in coronary vasomotion and ischemia. Circulation. 2001;104(10):1114–1118. doi:10.1161/hc3501.095338
  10. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Free Radic Biol Med. 2005;39(5):571–580. doi:10.1016/j.freeradbiomed.2005.04.001
  11. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46(3):325–415.
  12. Barton M. Endothelin and atherosclerosis. Cardiovasc Res. 2016;109(1):1–10. doi:10.1093/cvr/cvv240
  13. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Eur Heart J. 2009;30(2):139–149. doi:10.1093/eurheartj/ehn578
  14. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Eur Respir J. 2009;33(2):239–252. doi:10.1183/09031936.00082208
  15. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4–18. doi:10.2174/157016112798829760